Cargando…
Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
Several lines of evidence have supported the role of immunological mechanisms in the pathogenesis of multiple sclerosis (MS) and new immunomodulatory strategies for its treatment, e.g. subcutaneous application of interferon (IFN)-β, have emerged. We investigated the ability of peripheral blood monon...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science B.V.
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127026/ https://www.ncbi.nlm.nih.gov/pubmed/9168171 http://dx.doi.org/10.1016/S0022-510X(97)05383-5 |
_version_ | 1783516271912943616 |
---|---|
author | Wandinger, Klaus-Peter Wessel, Karl Neustock, Petra Siekhaus, Aja Kirchner, Holger |
author_facet | Wandinger, Klaus-Peter Wessel, Karl Neustock, Petra Siekhaus, Aja Kirchner, Holger |
author_sort | Wandinger, Klaus-Peter |
collection | PubMed |
description | Several lines of evidence have supported the role of immunological mechanisms in the pathogenesis of multiple sclerosis (MS) and new immunomodulatory strategies for its treatment, e.g. subcutaneous application of interferon (IFN)-β, have emerged. We investigated the ability of peripheral blood mononuclear cells (PBMC) in 21 consecutive patients with clinically definite MS to produce interferons and lymphokines in response to viral or mitogenic stimulation. Ten patients showed clinical signs of disease activity (acute relapse) and 11 patients were in a stable condition. Additionally, white blood count, leukocyte differentiation and lymphocyte subtyping were performed. A group of age-related healthy blood donors served as control (n=20). There was no difference between patients and controls in the production of IFN-γ, tumor necrosis factor (TNF)-α and soluble interleukin (IL)-2 receptor. IFN-α and IFN-β responsiveness, however, was significantly lower in patients with stable disease than in patients with active disease and controls (p<0.001). Furthermore, secretion of IL-2 after stimulation was significantly diminished in both patient groups as compared to the control group (p<0.01). Analysis of T-cell subsets revealed a significantly lower amount of CD8(+) T-cells in patients with stable disease, leading to a significantly higher CD4/CD8 ratio in this group as compared to patients with active disease. Our study depicted an IL-2 deficiency in MS patients which is shared with other autoimmune diseases. In addition, our findings suggest that the ability to produce type-I IFNs, IFN-α and IFN-β, is primarily impaired in MS patients and changes in correlation to the course of disease activity. |
format | Online Article Text |
id | pubmed-7127026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1997 |
publisher | Elsevier Science B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71270262020-04-08 Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis Wandinger, Klaus-Peter Wessel, Karl Neustock, Petra Siekhaus, Aja Kirchner, Holger J Neurol Sci Article Several lines of evidence have supported the role of immunological mechanisms in the pathogenesis of multiple sclerosis (MS) and new immunomodulatory strategies for its treatment, e.g. subcutaneous application of interferon (IFN)-β, have emerged. We investigated the ability of peripheral blood mononuclear cells (PBMC) in 21 consecutive patients with clinically definite MS to produce interferons and lymphokines in response to viral or mitogenic stimulation. Ten patients showed clinical signs of disease activity (acute relapse) and 11 patients were in a stable condition. Additionally, white blood count, leukocyte differentiation and lymphocyte subtyping were performed. A group of age-related healthy blood donors served as control (n=20). There was no difference between patients and controls in the production of IFN-γ, tumor necrosis factor (TNF)-α and soluble interleukin (IL)-2 receptor. IFN-α and IFN-β responsiveness, however, was significantly lower in patients with stable disease than in patients with active disease and controls (p<0.001). Furthermore, secretion of IL-2 after stimulation was significantly diminished in both patient groups as compared to the control group (p<0.01). Analysis of T-cell subsets revealed a significantly lower amount of CD8(+) T-cells in patients with stable disease, leading to a significantly higher CD4/CD8 ratio in this group as compared to patients with active disease. Our study depicted an IL-2 deficiency in MS patients which is shared with other autoimmune diseases. In addition, our findings suggest that the ability to produce type-I IFNs, IFN-α and IFN-β, is primarily impaired in MS patients and changes in correlation to the course of disease activity. Elsevier Science B.V. 1997-07-01 2000-03-15 /pmc/articles/PMC7127026/ /pubmed/9168171 http://dx.doi.org/10.1016/S0022-510X(97)05383-5 Text en Copyright © 1997 Elsevier Science B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wandinger, Klaus-Peter Wessel, Karl Neustock, Petra Siekhaus, Aja Kirchner, Holger Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis |
title | Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis |
title_full | Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis |
title_fullStr | Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis |
title_full_unstemmed | Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis |
title_short | Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis |
title_sort | diminished production of type-i interferons and interleukin-2 in patients with multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127026/ https://www.ncbi.nlm.nih.gov/pubmed/9168171 http://dx.doi.org/10.1016/S0022-510X(97)05383-5 |
work_keys_str_mv | AT wandingerklauspeter diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis AT wesselkarl diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis AT neustockpetra diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis AT siekhausaja diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis AT kirchnerholger diminishedproductionoftypeiinterferonsandinterleukin2inpatientswithmultiplesclerosis |